MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- ASTRAZENECA PHARMA (pharmaceuticals)
- Latest 8 Quarter Result
ASTRAZENECA PHARMA Quarterly Results (AIDL)
Here are the latest quarterly results of ASTRAZENECA PHARMA. For more details, see the ASTRAZENECA PHARMA financial fact sheet and ASTRAZENECA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
ASTRAZENECA PHARMA Quarterly Results
| No. of Mths Qtr. Ending |
3
Jun-19* |
3
Sep-19* |
3
Dec-19* |
3
Mar-20* |
3
Jun-20* |
3
Sep-20* |
3
Dec-20* |
3
Mar-21* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 2,046 | 2,085 | 2,239 | 1,949 | 1,936 | 2,095 | 2,003 | 2,103 | |
| Other income | Rs m | 30 | 32 | 35 | 34 | 26 | 47 | 29 | 26 | |
| Turnover | Rs m | 2,076 | 2,116 | 2,273 | 1,983 | 1,962 | 2,142 | 2,032 | 2,128 | |
| Expenses | Rs m | 1,690 | 1,749 | 1,871 | 1,801 | 1,650 | 1,737 | 1,695 | 1,698 | |
| Gross profit | Rs m | 356 | 336 | 368 | 148 | 286 | 358 | 307 | 404 | |
| Depreciation | Rs m | 46 | 46 | 48 | 45 | 46 | 46 | 51 | 58 | |
| Interest | Rs m | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |
| Profit before tax | Rs m | 336 | 318 | 352 | 134 | 264 | 356 | 283 | 368 | |
| Tax | Rs m | 121 | 174 | 85 | 38 | 78 | 92 | 72 | 96 | |
| Profit after tax | Rs m | 215 | 144 | 267 | 96 | 186 | 263 | 211 | 273 | |
| Gross profit margin | % | 17.4 | 16.1 | 16.4 | 7.6 | 14.8 | 17.1 | 15.4 | 19.2 | |
| Effective tax rate | % | 36.0 | 54.7 | 24.1 | 28.3 | 29.4 | 26.0 | 25.6 | 26.0 | |
| Net profit margin | % | 10.5 | 6.9 | 11.9 | 4.9 | 9.6 | 12.6 | 10.5 | 13.0 | |
| Diluted EPS | Rs | 8.6 | 5.8 | 10.7 | 3.8 | 7.5 | 10.5 | 8.4 | 10.9 | |
| Diluted EPS (TTM) | Rs | NA | NA | 29.0 | 28.9 | 27.7 | 32.5 | 30.2 | 37.3 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: ASTRAZENECA PHARMA 3QFY21 Result Performance Review
More Pharmaceuticals Company Quarterly Results: REKVINA LABS NOVARTIS IPCA LABS SONI MEDICARE NEULAND LABS
Compare ASTRAZENECA PHARMA With: REKVINA LABS NOVARTIS IPCA LABS SONI MEDICARE NEULAND LABS
Compare ASTRAZENECA PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Sensex Opens Flat; Hindalco & Hero MotoCorp Top Gainers(09:30 am)
Asian share markets are steady today after reassuring comments on inflation and monetary policy from Federal Reserve officials bolstered investor sentiment.
Views on news
ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)
Feb 11, 2021 | Updated on Feb 11, 2021For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)
Sep 22, 2020 | Updated on Sep 22, 2020For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
Points to Keep in Mind Before Subscribing to Krishna Institute of Medical Sciences' IPO (Views On News)
Jun 15, 2021All you need to know about the IPO of Krishna Institute of Medical Sciences.
Why Did Shares of Divi's Lab Rally Today? (Views On News)
Jun 10, 2021The stock jumped 3.6% in intraday trade to hit its 52-week high.
Laurus Labs Hits New Life High. Up 500%+ in One Year (Views On News)
Jun 8, 2021Laurus Labs trades higher for the eight straight day, soars 73% in 3 months.
More Views on NewsMost Popular
My 'Unlock' Investments (Fast Profits Daily)
Jun 11, 2021The best unlock investments you can make in the market.
How I Discovered a 400-Year-Old Open Secret to Extreme Wealth (Profit Hunter)
Jun 11, 2021Charlie Munger's open secret about investing success.
Cut the Noise and Hold these Stocks FOREVER (Profit Hunter)
Jun 17, 2021A sure shot way of creating wealth is to not disturb the process of compounding.
Wednesday's Market Fall Explained (Fast Profits Daily)
Jun 10, 2021This is why the stock market fell the way it did on Wednesday.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
ASTRAZENECA PHARMA SHARE PRICE
Jun 23, 2021 10:39 AM
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA - BAL PHARMA COMPARISON
COMPARE ASTRAZENECA PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.